PSNL at a glance
Personalis, Inc. (PSNL, SEC CIK 1527753) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Personalis, Inc. (PSNL) reported revenue of $69.6 million (down 17.7% from FY2024) and a net loss of $81.3 million. Diluted EPS was -$0.91.
- As of September 30, 2026, 28 institutional investment managers tracked by SignalX reported holding Personalis, Inc. (PSNL) shares worth $707.6 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Hall Christopher M on November 3, 2026 of 29,112 shares at $15.87 per share.
- In the last 90 days, PSNL insiders reported 0 open-market purchases ($0) and 5 open-market sales ($729K) on Form 4, a net sale of $729K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $69.6M
- −17.7% vs prior year
- Insiders · 90 days
- 0 buys · 5 sells
- Net −$729K
- 13F holders
- 28 funds
- $707.6M · +1 vs prior quarter
- Latest 8-K
- Nov 4, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Pending Tempus merger, stockholder vote scheduled November 30, 2026, creates new completion and timing risk
- Merger consideration, fixed exchange ratio 0.3356 below Tempus Floor Price $48.42, could value shares below $16.25
- New tariff exposure, announced U.S. tariffs may raise laboratory costs that fixed-price contracts cannot immediately recover
- Regulatory compliance, FDA could require medical-device authorization for LDTs, adding premarket review and ongoing obligations
- Customer concentration, Moderna 13%, VA MVP 15%, and Merck 27% of nine-month 2026 revenue intensify renewal risk
Management Discussion & Analysis
- Q3 revenue $25.6M, up 77% YoY from $14.5M, driven by pharma, clinical diagnostics and population sequencing
- Operating margin -138.8% vs -160.7% YoY, calculated from operating losses of $35.5M and $23.3M
- Best segment: clinical diagnostics $4.4M, up 1,039% YoY; worst: enterprise sales, down 99%
- Cash and investments $190.6M vs $240.0M at year-end; nine-month operating cash use $75.3M
- 2026 capital expenditures expected at $10.0M-$12.0M; headwinds include reimbursement-related testing costs and Merger uncertainty
AI summary of the PSNL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Personalis announced financial results for the quarter ended September 30, 2026
- Investors should review Exhibit 99.1 for revenue, profitability, cash position and management commentary
Item EX-99.1: Item EX-99.1
- Q3 revenue $25.6M, up from $14.5M, driven by clinical testing, pharma services and population sequencing
- Clinical volume 13,157 tests versus 4,388, with clinical revenue rising to $4.4M from $0.4M
Item 8.01: Other Events
- HSR antitrust waiting period expired October 2, 2026, removing a major regulatory closing condition
- Tempus acquisition still requires Personalis stockholder approval and satisfaction or waiver of remaining conditions
Item 8.01: Other Events
- New VA MVP task order valued up to $18.3 million, effective September 30, 2026
- Cumulative VA MVP task-order value increased to approximately $243.3 million
AI summaries of PSNL 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for PSNL
Don't miss the next PSNL filing
- Alerts as it files. A push when PSNL files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut PSNL, by share count.
- Ask anything. An AI agent that reads every PSNL filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Hall Christopher M | Sell | Nov 3, 2026 | 29,112 | $15.87 |
| Chen Richard | Sell | Sep 18, 2026 | 3,998 | $16.22 |
| Moore Stephen Michael | Sell | Sep 18, 2026 | 2,068 | $16.22 |
| Tachibana Aaron | Sell | Sep 18, 2026 | 2,931 | $16.22 |
| Hall Christopher M | Sell | Sep 18, 2026 | 7,459 | $16.22 |
| Chen Richard | M | Jul 15, 2026 | 100,000 | $2.44 |
| Chen Richard | Sell | Jul 15, 2026 | 100,000 | $15.15 |
| Chen Richard | M | Jul 15, 2026 | 100,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $84.6M | $69.6M |
| Operating Income | -$109.9M | -$68.3M | -$88.1M |
| Net Income | -$108.3M | -$81.3M | -$81.3M |
| Op. Margin | - | -80.7% | -126.4% |
| Net Margin | - | -96.1% | -116.7% |
| Balance Sheet | |||
| Total Assets | - | $270.3M | $334.2M |
| Equity | - | $203.0M | $261.2M |
| ROE | - | -40.0% | -31.1% |
| Per Share | |||
| EPS | $-2.25 | $-1.37 | $-0.91 |
| Cash Flow | |||
| Operating CF | - | -$45.1M | -$74.9M |
| CapEx | $10.9M | $1.6M | $4.5M |
Source: XBRL data in Personalis, Inc. (PSNL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate PSNL share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 28 | $707.6M |
| Q2 2026 | 27 | $645.0M |
| Q1 2026 | 26 | $287.7M |
| Q4 2025 | 25 | $333.0M |
| Q3 2025 | 24 | $236.5M |
| Q2 2025 | 24 | $229.7M |
| Q1 2025 | 21 | $93.6M |
| Q4 2024 | 16 | $149.6M |
- T. Rowe Price Group+1.02M (+643%)
- Millennium Management+655.1K (+146%)
- Two Sigma Investments+624.8K (+1091%)
- Vanguard Capital Management LLC+259.6K (+9%)
- Goldman Sachs Group+173.9K (+19%)
- Ameriprise Financial−4.98M (-82%)
- ARK Investment Management−1.15M (-14%)
- Morgan Stanley−654.8K (-52%)
- Bank of America Corp−486.7K (-27%)
- Dimensional Fund Advisors−263.4K (-18%)
- Soros Fund Management+250.0K
- StoneX Group Inc.+11.4K
- FMR LLC (Fidelity)−4.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 191 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
PSNL filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 4, 2026 | - | - | - |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 10-Q | Nov 4, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 6, 2026 | - | Analysis | - |
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 22, 2026 | - | - | - |
| 8-K | Aug 20, 2026 | - | Analysis | - |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 10-Q | Aug 4, 2026 | Jun 30, 2026 | Analysis | |
| SC 13G | Jul 29, 2026 | - | - | |
| 8-K | Jul 20, 2026 | - | Analysis | - |
| 8-K | Jul 20, 2026 | - | Analysis | - |
| 4 | Jul 15, 2026 | - | - | - |
| 4 | Jul 9, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 5, 2026 | - | - | |
| 4 | May 29, 2026 | - | - | |
| 4 | May 29, 2026 | - | - | |
| 8-K | May 20, 2026 | - | Analysis | |
| 4 | May 14, 2026 | - | - |
Related Health Care companies
- CDNA · CareDx, Inc.Services-Medical Laboratories
- CSTL · CASTLE BIOSCIENCES INCServices-Medical Laboratories
- CELC · Celcuity Inc.Services-Medical Laboratories
- FTRE · Fortrea Holdings Inc.Services-Medical Laboratories
- FLGT · Fulgent Genetics, Inc.Services-Medical Laboratories
- GRAL · GRAIL, Inc.Services-Medical Laboratories
- GH · Guardant Health, Inc.Services-Medical Laboratories
- LH · LabcorpServices-Medical Laboratories
PSNL SEC filings: frequently asked questions
Are PSNL insiders buying or selling?
In the last 90 days, Personalis, Inc. (PSNL) officers, directors and 10% owners reported no open-market purchases and 5 open-market sales worth $728,924 by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold PSNL stock?
As of September 30, 2026, the largest Personalis, Inc. (PSNL) holders among the 13F filers tracked by SignalX were Merck & Co. ($228.7 million), ARK Investment Management ($115.9 million), BlackRock ($112.9 million), Vanguard Capital Management LLC ($53.2 million), State Street Corp ($25.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was PSNL's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Personalis, Inc. (PSNL) reported revenue of $69.6 million (down 17.7% from FY2024) and a net loss of $81.3 million. Diluted EPS was -$0.91. The figures come from the XBRL data in the 10-K.
What did PSNL report in its latest 8-K?
Personalis, Inc. (PSNL) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Personalis announced financial results for the quarter ended September 30, 2026.
What are the latest PSNL SEC filings?
Personalis, Inc. (PSNL) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 4, 2026.
What is PSNL's SEC CIK number?
Personalis, Inc. (PSNL)'s SEC Central Index Key (CIK) is 1527753. EDGAR lists every PSNL filing under that number.
Ask anything about PSNL
The research agent reads PSNL's filings, financials, insider trades and 13F holders, then answers with sources.